A dizzying flurry of biotech and pharmaceutical acquisitions may not slow soon.
"I think we'll look segment by segment and we'll do acquisitions where it will strengthen our business," Pfizer CEO Ian Read said on CNBC Thursday in a "Power Lunch" interview.
Among other moves, the company in February announced a $17 billion acquisition of Hospira, which is a leader in injected drugs. Read noted that the company would look at not only "innovative" segments but also at products that build on current Pfizer offerings.
In a separate CNBC interview Thursday, Merck CEO Kenneth Frazier said the company was open to expanding some segments through acquisitions. The company bought both hepatitis C treatment maker Idenix and drugmaker Cubist in the last year.
Frazier made the distinction between finding "the next wave of science" and strengthening existing business.
Merck may make moves in "spaces where we're either leading or where we aspire to lead going forward," he added.
Pfizer was trading barely positive while Merck was nearly 1 percent lower on Thursday.